Abstract:Background: Gliomas and glioblastomas (GBM) are common primary malignant brain tumors, which are highly malignant and have a poor prognosis. The presence of cancer stem cells with unrestricted proliferative capacity and ability to generate glial neoplastic cells, the diffuse nature of GBM, and other specific factors of GBM contribute to poor results of drug therapy in patients with GBM. Despite the worldwide efforts to improve the treatment, many novel anti-GBM drugs are active just in vitro, in silico, and in preclinical trials, and they sometimes demonstrate poor or no activity in clinical trials. In this paper, we have casually selected and analyzed the most promising evidence-based results related to glioblastoma treatment at FDA and Clinical Trials.gov databases. It was observed that the most prospective trend in the development of anti-GBM drugs is combination therapy vs. monotherapy. Our analysis of clinical trials has allowed us to predict that the most promising combination therapy that has shown the best results in patient’s surveillance should include drugs that block different growth-promoting signals in glioblastoma cells and that are activated by the V600E BRAF mutation. One drug should inhibit signals from the BRAF protein, whereas the second drug in combination should inhibit signals from the MEK protein Methods: The content of this review is based on information obtained from PubMed, ClinicalTrials. gov, and the U.S. Food and Drug Administration (https://www.fda.gov/). In ClinicalTrials.gov, we retrieved studies published from January 1, 2015. In the data search, “Glioblastoma” was used as the keyword. A study was deleted if it studied remedies for concomitant tumor diseases, as well as if it did not include descriptions of treatment methods and/or if GBM was not mentioned. The analysis of the effectiveness of treatment was carried out according to the increasing overall survival in GBM patients, compared to the gold standard for this cancer. Results: GBM patients treated with novel immunotherapy agents and drugs acting on epigenetic factors and receptor tyrosine kinase inhibitors have shown encouraging potential for future development in clinic. However, combinations of drugs have led to more significant improvements in the results and an increase in life expectancy of patients. For example, the combination of nivolumab and ipilimumab showed a 72% increase in life expectancy compared to using nivolumab alone (9.8 vs. 16.85). Conclusion: Combining anti-GBM drugs appears to be a key direction for increasing treatment effectiveness and overall survival. Radiotherapy of GBM can increase the effect of combination drug therapy.

Effectiveness of Different Treatment Strategies in Elderly Patients with Glioblastoma: an Evidence Map of Randomized Controlled Trials.

Implementation Of Clinical Practice Guidelines For Newly Diagnosed Gbm Patients In China.

Treatment Strategies for Glioblastoma in the Elderly: What Should We Focus on Compared to Younger Patients

Competing risk model to determine the prognostic factors and treatment strategies for elderly patients with glioblastoma

Targeted agents in patients with progressive glioblastoma—A systematic meta‐analysis of randomized clinical trials

Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis

Prognostic and Predictive Factors in Elderly Patients With Glioblastoma: A Single-Center Retrospective Study

The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials

Current chemotherapy strategies for adults with IDH-wildtype glioblastoma

Analysis of Clinical Success and Molecular Mechanisms of Action of Novel Anti-glioblastoma Drugs: A Review

Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis

Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials

Glioblastoma in elderly patients: A retrospective analysis of survival and response based on molecular and clinical characteristics—Experience in our centre.

Pharmacological strategies for improving the prognosis of glioblastoma

Emerging therapies for glioblastoma: current state and future directions

Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme

Approaches in Adult Glioblastoma Treatment: A Systematic Review of Emerging Therapies

Abstract 94: Utilization of MGMT Promoter Methylation Status to Guide Treatment in Elderly Patients With Glioblastoma

Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis